Experimental diabetes mellitus exacerbates Tau pathology in a transgenic mouse model of Alzheimer's disease

Ke, Yazi D., Delerue, Fabien, Gladbach, Amadeus, Gotz, Jurgen and Ittner, Lars M. (2009) Experimental diabetes mellitus exacerbates Tau pathology in a transgenic mouse model of Alzheimer's disease. PLoS ONE, 4 11: e7917.1-e7917.7. doi:10.1371/journal.pone.0007917


Author Ke, Yazi D.
Delerue, Fabien
Gladbach, Amadeus
Gotz, Jurgen
Ittner, Lars M.
Title Experimental diabetes mellitus exacerbates Tau pathology in a transgenic mouse model of Alzheimer's disease
Journal name PLoS ONE   Check publisher's open access policy
ISSN 1932-6203
Publication date 2009-11
Year available 2009
Sub-type Article (original research)
DOI 10.1371/journal.pone.0007917
Open Access Status DOI
Volume 4
Issue 11
Start page e7917.1
End page e7917.7
Total pages 7
Place of publication San Francisco United States
Publisher Public Library of Science (PLoS)
Language eng
Abstract Diabetes mellitus (DM) is characterized by hyperglycemia caused by a lack of insulin, insulin resistance, or both. There is increasing evidence that insulin also plays a role in Alzheimer's disease (AD) as it is involved in the metabolism of β-amyloid (Aβ) and tau, two proteins that form Aβ plaques and neurofibrillary tangles (NFTs), respectively, the hallmark lesions in AD. Here, we examined the effects of experimental DM on a pre-existing tau pathology in the pR5 transgenic mouse strain that is characterized by NFTs. pR5 mice express P301L mutant human tau that is associated with dementia. Experimental DM was induced by administration of streptozotocin (STZ), which causes insulin deficiency. We determined phosphorylation of tau, using immunohistochemistry and Western blotting. Solubility of tau was determined upon extraction with sarkosyl and formic acid, and Gallyas silver staining was employed to reveal NFTs. Insulin depletion by STZ administration in six months-old non-transgenic mice causes increased tau phosphorylation, without its deposition or NFT formation. In contrast, in pR5 mice this results in massive deposition of hyperphosphorylated, insoluble tau. Furthermore, they develop a pronounced tau-histopathology, including NFTs at this early age, while the pathology in sham-treated pR5 mice is moderate. Whereas experimental DM did not result in deposition of hyperphosphorylated tau in non-transgenic mice, a predisposition to develop a tau pathology in young pR5 mice was both sufficient and necessary to exacerbate tau deposition and NFT formation. Hence, DM can accelerate onset and increase severity of disease in individuals with a predisposition to developing tau pathology.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: Queensland Brain Institute Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 85 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 92 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 26 Feb 2014, 08:34:31 EST by System User on behalf of Queensland Brain Institute